Evonik invests in Singapore organ-on-a-chip start-up

The Edge Singapore
The Edge Singapore11/30/2021 5:7 PM GMT+08  • 2 min read
Evonik invests in Singapore organ-on-a-chip start-up
Commercialising organ-on-a-chip technology will make testing quicker, more reliable, cost-efficient and more ethical.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

German specialty chemicals company Evonik has invested in Singapore start-up Revivo BioSystems, which provides an alternative to animal testing.

The investment -- which is Evonik’s first direct investment in the city-state -- will support the development and commercialisation of a technology that uses a realistic 4D model of human skin for the testing of chemical, cosmetic and pharmaceutical compounds.

Revivo BioSystems’s organ-on-a-chip system simulates the interaction of human skin with the substance being tested.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.